亚宝药业(600351.SH)发布前三季度业绩，归母净利润2.15亿元，同比下降8.44%

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved a revenue of 1.709 billion yuan, representing a year-on-year decrease of 19.46% [1] - The net profit attributable to shareholders was 215 million yuan, down 8.44% year-on-year [1] - The non-recurring net profit was 197 million yuan, reflecting a decline of 9.03% compared to the previous year [1] - The basic earnings per share stood at 0.3066 yuan [1]